Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

The American Pharmacists Association (APhA) has selected seven recipients of its 2025 Immunization Champion Awards, ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...